SGLT2 inhibitors have become increasingly used due to their effectiveness in improving not only type 2 diabetes but also cardiovascular, renal and hepatic diseases, as well as the obesity found in metabolic syndrome. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.